ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)

Continuing to challenge the current HIV treatment paradigm, data presented will span our diverse portfolio, investigating new and innovative treatment options for people living with HIV.

London, 2 July 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, and its clinical trial partners, will be presenting over 20 abstracts during next week at the 23rd International AIDS Conference (AIDS 2020 Virtual), being held 6-10 July. Because of the COVID-19 pandemic, the conference will, for the first time, be completely virtual.

Highlights from ViiV Healthcare and study partners at AIDS 2020 will include the final efficacy analysis from the global HIV Prevention Treatment Network (HPTN ) 083 study evaluating investigational long-acting cabotegravir for HIV prevention; 48-week data from CUSTOMIZE, an implementation research study on how to implement, if approved, a new, once-monthly injectable HIV treatment in US healthcare practices; and results from the Positive Perspectives Wave 2 study, providing extensive insights from more than 2,300 people living with HIV (PLHIV) in 25 countries.

ViiV Healthcare’s commitment towards ending paediatric AIDS by 2025 will be showcased with a media panel to introduce the new Positive Action Breakthrough grants alongside our global partners selected to receive ViiV Healthcare funding, and a satellite symposium on delivering an Integrated Approach for Adolescent Mothers and their Children.

Kimberly Smith, Head of Research & Development, ViiV Healthcare, said: “The data we’re presenting at AIDS 2020 show the continued depth and focus of ViiV Healthcare’s patient-centred approach to innovation and the strength of our commitment to the community. We’ll be sharing the significant advances we’ve made not just for the treatment of HIV, but for prevention as well, in some of the populations most disproportionately impacted by HIV. We’ll also share the in-depth insights gained from more than 2,300 people living with HIV that will help address their treatment needs and challenges.”

Key abstracts to be presented by ViiV Healthcare and study partners at AIDS 2020

Final efficacy analysis from the global HPTN 083 study evaluating cabotegravir for HIV prevention: The HPTN 083 study, with approximately 4,600 participants across 40 sites in North and South America, Asia and Africa, is one of the first-ever clinical trials to directly compare two active HIV prevention agents. In a planned interim review, the independent Data and Safety Monitoring Board recommended the blinded, randomized portion of the study be stopped early and results released. Detailed final efficacy results from this interim review will be presented at AIDS 2020.

48-week findings from the implementation research study, CUSTOMIZE (Cabotegravir plus Rilpivirine in the US To Optimize and Measure Implementation and Experience): Data to be presented at AIDS 2020 will outline the quantitative findings from ViiV Healthcare’s implementation research study, CUSTOMIZE. ViiV Healthcare worked with 24 healthcare providers and clinic administrators from eight sites to identify and evaluate approaches to implementing the investigational once-monthly, long-acting, investigational regimen of cabotegravir and rilpivirine for the treatment of HIV, into clinical practice. Long-acting treatments have the potential to change HIV management by replacing daily pills with long-acting dosing regimens, and results from the CUSTOMIZE trial will help to find solutions to real-world challenges in implementing such treatments.

Global Positive Perspectives Wave 2 study results: ViiV Healthcare will showcase results from the second wave of Positive Perspectives research at AIDS 2020. The study captured insights from more than 2,300 people living with HIV from 25 countries and the results highlight the importance of a holistic approach involving people living with HIV in open dialogue and joint decision-making with their healthcare providers. The external Positive Perspectives advisory committee also developed a manifesto, in partnership with ViiV Healthcare, containing specific recommendations for policymakers to include quality of life in assessments and encourage open and active dialogue, which will be outlined at the conference.